Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B2033 vs Sorafenib or Lenvatinib in Hepatocellular Carcinoma
NCT07836530Phase 3Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2026
- Primary completion
- Sep 2029
01
Overview
Phase 3, randomised, open-label trial of BGB-B2033 in hepatocellular carcinoma (HCC) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Overall Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BGB-B2033
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07836530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836530.